Cochrane · systematic review · CD007110
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
Blank, O, von Tresckow, B, Monsef, I, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
13
No studies
1
Included studies
NR
No studies 1 · 7.1%Ungraded 0 · 0%Very low 0 · 0%Low 9 · 64.3%Moderate 4 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySame number of chemotherapy cycles in both arms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (calculated instead of overall survival) | HR 0.48 [0.22, 1.06] | 5 studies · 1388 participants | Moderate Downgraded: inconsistency |
Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias | HR 0.31 [0.19, 0.52] | 3 studies · 816 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Relapse, progression or death (calculated instead of PFS) | HR 0.42 [0.25, 0.72] | 4 studies · 1351 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Infection‐ related mortality | RR 0.33 [0.01, 8.06] | 1 study · 152 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Second cancer‐ related mortality | RR 0.53 [0.07, 4.29] | 3 studies · 1199 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Cardiac disease‐ related mortality | RR 2.94 [0.31, 27.55] | 2 studies · 457 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Complete response rate | RR 1.08 [0.93, 1.25] | 3 studies · 376 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Different numbers of chemotherapy cycles in both arms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (calculated instead of overall survival) | HR 2.12 [1.03, 4.37] | 1 study · 276 participants | Low Downgraded: imprecision |
Relapse, progression or death (calculated instead of PFS) | HR 0.42 [0.14, 1.24] | 3 studies · 1176 participants | Low Downgraded: imprecision, inconsistency |
Relapse, progression or death (calculated instead of PFS) sensitivity analysis ‐ without HD6trial due to high risk of other bias | HR 0.24 [0.07, 0.88] | 900 participants | Moderate Downgraded: imprecision, inconsistency |
Infection‐ related mortality | RR 6.9 [0.36, 132.34] | 1 study · 276 participants | Low Downgraded: imprecision |
Second cancer‐ related mortality | RR 2.22 [0.7, 7.03] | 1 study · 276 participants | Low Downgraded: imprecision |
Cardiac disease‐ related mortality | RR 0.99 [0.14, 6.9] | 1 study · 276 participants | Low Downgraded: imprecision |
Complete response rate | no estimate extracted | NR | No studies |
Summary of Findings Table
Population: Early stage Hodgkin lymphoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Hazard Ratio ( | HR 0.4 [0.27, 0.6] | 5 studies · 1245 participants | Moderate |
Tumour control ( | HR 0.41 [0.25, 0.66] | 4 studies · 1202 participants | Moderate |
Complete Response Rate | RR 1.07 [0.98, 1.17] | 4 studies · 653 participants | Moderate |
Long term secondary malignancies | no estimate extracted | NR | No studies |
Acute adverse effects | no estimate extracted | NR | No studies |
Long term toxicities | no estimate extracted | NR | No studies |